How to buy Rigel Pharmaceuticals stock (RIGL)

Rigel Pharmaceuticals is a biotechnology business based in the US. Rigel Pharmaceuticals shares (RIGL) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $17.21 – a decrease of 8.99% over the previous week. Rigel Pharmaceuticals employs 147 staff and has a trailing 12-month revenue of around $157.4 million.

Our top picks for where to buy Rigel Pharmaceuticals stock

Buy Rigel Pharmaceuticals stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Rigel Pharmaceuticals stock price (NASDAQ: RIGL)

Use our graph to track the performance of RIGL stocks over time.

Rigel Pharmaceuticals shares at a glance

• Key figures

Information last updated 2024-12-18.

Latest market close	$17.21
52-week range	$7.48 - $29.82
50-day moving average more info button	$19.90
200-day moving average more info button	$13.74
Wall St. target price	$31.33
PE ratio more info button	63.2222
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$0.27

Is it a good time to buy Rigel Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Rigel Pharmaceuticals price performance over time

Historical closes compared with the close of $17.07 from 2024-12-18

1 week (2024-12-13)	-9.73%
1 month (2024-11-21)	-31.83%
3 months (2024-09-20)	24.06%
6 months (2024-06-20)	1,687.06%

1 year (2023-12-20)	1,287.80%
2 years (2022-12-20)	44.05%
3 years (2021-12-20)	26.7
5 years (2019-12-20)	21.1

Is Rigel Pharmaceuticals stock undervalued or overvalued?

Valuing Rigel Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Rigel Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Rigel Pharmaceuticals's P/E ratio

Rigel Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 63x. In other words, Rigel Pharmaceuticals shares trade at around 63x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Rigel Pharmaceuticals's EBITDA

Rigel Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $11.3 million.

The EBITDA is a measure of a Rigel Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.

Rigel Pharmaceuticals financials

Revenue TTM	$157.4 million
Operating margin TTM	25.42%
Gross profit TTM	$53.7 million
Return on assets TTM	4.61%
Return on equity TTM	-699.05%
Profit margin	2.47%
Book value	$-0.83
Market Capitalization more info button	$300.7 million

TTM: trailing 12 months

Rigel Pharmaceuticals share dividends

We're not expecting Rigel Pharmaceuticals to pay a dividend over the next 12 months.

Have Rigel Pharmaceuticals's shares ever split?

Rigel Pharmaceuticals's shares were split on a 1:10 basis on 26 June 2024 . So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Rigel Pharmaceuticals shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Rigel Pharmaceuticals shares which in turn could have impacted Rigel Pharmaceuticals's share price.

Rigel Pharmaceuticals share price volatility

Over the last 12 months, Rigel Pharmaceuticals's shares have ranged in value from as little as $7.4843 up to $29.82. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Rigel Pharmaceuticals's is 0.953. This would suggest that Rigel Pharmaceuticals's shares are less volatile than average (for this exchange).

Rigel Pharmaceuticals overview

Rigel Pharmaceuticals, Inc. , a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.

Frequently asked questions

What percentage of Rigel Pharmaceuticals is owned by insiders or institutions?
Currently 2.182% of Rigel Pharmaceuticals shares are held by insiders and 68.011% by institutions. How many people work for Rigel Pharmaceuticals?
Latest data suggests 147 work at Rigel Pharmaceuticals. When does the fiscal year end for Rigel Pharmaceuticals?
Rigel Pharmaceuticals's fiscal year ends in December. Where is Rigel Pharmaceuticals based?
Rigel Pharmaceuticals's address is: 611 Gateway Blvd, South San Francisco, CA, United States, 94080 What is Rigel Pharmaceuticals's ISIN number?
Rigel Pharmaceuticals's international securities identification number is: US7665596034 What is Rigel Pharmaceuticals's CUSIP number?
Rigel Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 766559108